Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $2M rose 37.2% year over year, ahead of the -52.9% change in trailing-twelve-month revenue. Sequentially, it rose 54.1% from the prior quarter. Over 3 fiscal years it compounded at -35.9% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 7 analysts of $6.37M (-18.6%) for the fiscal year ending Dec 2026, a step up from the -58.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2M+54.1% QoQ
Last fiscal yearDec 2025
$7.83M-58.2% YoY
LTMMar 2026
$8.37M-52.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.2%-22.2%-59.4 pp
1 year-58.2%-18.6%+39.6 pp
3-year CAGR-35.9%-6.1%+29.8 pp
5-year CAGR+59.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
7.83M USD
Year-over-year change
-58.2%
4-year CAGR
+3.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -52.9% is the 2nd highest of 4, against a peer median of -63.1%.
  • Over three fiscal years its annual growth of -35.9% compares with a peer median of +183.6%.
ACRS Competitors
Revenue for ACRS and competitors
Company Period LTM YoY 3-year CAGR
ANABAnaptysBio, Inc.LTM Mar 2026$232.39M USD+107.7%+183.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$8.37M USD-52.9%-35.9%
ALMSAlumis Inc. Common StockLTM Jun 2026$7.4M USD-63.1%—
ATTOAttovia Therapeutics, Inc.FY2025$1.35M USD——
IFRXInflaRx N.V.LTM Mar 2026€29.33K EUR-77.4%—
TRAXFirst Tracks Biotherapeutics IncFY2025$0 USD——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$0 USD——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR——
IMUXImmunic, Inc.LTM Mar 2026$0 USD——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD——
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding ACRS) —-63.1%+183.6%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.